Merck expands cGMP facility, offering full end-to-end solution for BioPharm customers

Flexible factory concept allows accelerated drug development and delivery to market.

"Our aim is to facilitate accelerated drug development and delivery via continued innovation and technical expertise by offering customers a complete end-to-end solution from clone to commercial production," said Udit Batra, CEO, Life Science at Merck. "Our unique offering gives customers the choice to transfer their production at any stage with the confidence that we will ensure the most efficient transition into commercial manufacturing - at either an existing facility or one we help them design."

With this increase in scale and scope, Merck can advance clients' recombinant products from cell line development through to late-stage clinical production. At the point of tech transfer out to a contract manufacturing organization or other facility, clients can also leverage Merck's Provantage End-to-End Services available worldwide to mitigate the risks traditionally associated with upscaling to commercial production.

Merck's Provantage End-to-End solution is a comprehensive suite of products and services that include process development, cGMP manufacturing, facility design, manufacturing equipment and consumables, process and equipment training, technology transfer and set-up for commercialization. The offering aims to minimize the risks for customers progressing from early clinical stages to commercial production helping to accelerate time to market and improve productivity and profitability.